Empamore by Morepen: Revolutionizing Diabetes Care with Affordable, High-Quality Treatment

Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). With India being the diabetes capital of the world and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health.

Empamore: More Safety, More Efficacy, More Affordability

Morepen manufactures Empagliflozin (API) in its USFDA-approved facilities and already has European DMF. The launch of Empamore reflects Morepen's 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality. The product range includes:

- Empagliflozin (Empamore 10mg/25mg)
- Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg)

Empagliflozin is a globally recognized SGLT2 inhibitor, widely used for diabetes management. With prediabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.9%, Morepen's launch of Empamore comes at a crucial time to provide an affordable and effective solution.

Bridging the Healthcare Gap with Affordable Access

Speaking on the launch, Ashutosh Sharma, V.P. - Sales & Marketing, Morepen Laboratories, said: "At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without Þnancial strain. This aligns with our commitment to empower people to take charge of their health."

Competitive Pricing & Nationwide Availability

The market price of Empagliflozin tablets has historically been high, making it inaccessible for many. With Morepen's launch of Empamore at a fraction of the cost, the company aims to capture a significant share of the rapidly growing diabetes market in India, ensuring that quality treatment is no longer a privilege but a right for every patient.

Morepen's Legacy in Diabetes Care

Morepen has been a pioneer in diabetes management solutions, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips. Empamore is a natural extension of Morepen's commitment to empowering people with "Health in Your Hands", offering them the tools they need to prevent, monitor, and treat diabetes effectively.

Empamore: RedeÞning Patient-Centric Diabetes Care

- Unmatched Affordability: Priced significantly lower than leading brands, ensuring access for all.
- Comprehensive Diabetes Solution: Beyond glycemic control, it addresses cardiovascular and renal complications.
- Global Quality Standards: Manufactured at Morepen's USFDA-approved plant with DMF-grade quality, ensuring top-tier safety and efficacy.
- Innovative Packaging: Designed with perforated strip packaging for convenience and adherence, making daily management easier for patients.

Serving India & The World

With an extensive global footprint spanning 82 countries, Morepen continues to raise the bar in pharmaceutical innovation. The launch of Empamore reflects the company's dedication to bringing affordable healthcare solutions to millions, not just in India but worldwide.

Shares of Morepen Laboratories Limited was last trading in BSE at Rs. 42.80 as compared to the previous close of Rs. 44.66. The total number of shares traded during the day was 704444 in over 6887 trades.

The stock hit an intraday high of Rs. 45.32 and intraday low of 42.55. The net turnover during the day was Rs. 30764061.00.

Source : Equity Bulls

Keywords

MorepenLaboratories INE083A01026 Pharmaceuticals Empamore DiabetesCare HighQualityTreatment CKD